Moderna’s Stronger Vaccine AdComm Vote Indicative Of Second Mover Advantage, Not Data Profile

 
• By Sarah Karlin-Smith

Moderna’s COVID-19 vaccine got a more solid ‘yes’ vote than Pfizer/BioNTech’s, but committee chair cautions against drawing any comparisons between the products from the different tallies. Last-minute bickering over FDA’s phrasing of voting question complicated meeting but resulted in minimal harm.

Biotechnology company Moderna protocol files for COVID-19 vaccinations are kept at the Research Centers of America in Hollywood, Florida, on August 13, 2020. (Photo by Chandan Khanna/ AFP) (Photo by CHANDAN KHANNA/AFP via Getty Images)
Moderna was able to take notes on what worked and what didn't at Pfizer's advisory committee the week before. • Source: Chandan Khanna/AFP via Getty Images

More from US FDA Performance Tracker

More from Regulatory Trackers